Company intelligence / Profile preview
KangaBio
Shanghai, Shanghai, Chinakangabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
KGX101, a tumor-specific recombinant IL-12 Fc fusion protein, has received FDA approval for Phase I clinical trials. Patient screening has been initiated in several Australian clinical research centers.
- Therapeutic areas
- Oncology
- Modalities
- Prodrugs of immune-stimulating agentsmultispecific antibodiesantibody fusion proteinsrecombinant protein prodrugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Aton Biotech (CDMO services)Sanyou Biopharmaceuticals
Beyond the preview
Go deeper on KangaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KangaBio.